Oncotelic presents clinical data confirming TGF-β2 as target for gliomas; OS improvements shown

Oncotelic Therapeutics, Inc.

Reduced TGF-β2 increased OS from 9 to 22 mos in pediatric brainstem patients (N=95, p<0.0001).
In glioma patients treated with TMZ, reduced TGF-β2 improved OS from 25 to 94 mos (N=230, p<0.0001).
Similar OS improvement from 25 to 94 mos with radiation therapy (N=293, p<0.0001).
Company states failure of GSK's bintrafusp alfa (TGF-β1 trap) validates focus on TGF-β2 isoform.
Data presented at AACR-JCA Joint Conference Dec 10-14, 2022 in Maui.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.